BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation theory Inoculation in this area improves peoples resistance to such attacks, examples and directions for future work are provided. Recent studies have approached inoculation by incorporating psychological reactance theory (Brehm, 1966, 1972; Brehm & Brehm, 1981) as a means to enhance resistance outcomes through inoculation theory's two key components: threat and refutational preemption. Miller, et al. (2013) focused their study on emerging adults and their reactance to persuasive appeals. Research has demonstrated that this population is in a transitional stage in life (Voyer et al., 2005) and are more likely to defend their behavioral freedoms if they feel others are attempting